The Effect of Early Repeat Atrial Fibrillation (AF) Ablation on AF Recurrence

Atrial Fibrillation Clinical Trial

— PRESSURE  

Official title:

Pulmonary Vein Re-isolation as a Routine Strategy: a Success Rate Evaluation

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01942408
• Other study ID #: LHCH967
• Secondary ID: BWI-IIS-0239
• Status: Completed
• Phase: N/A
• First received: September 10, 2013
• Last updated: March 2, 2016
• Start date: November 2013
• Est. completion date: February 2016

Study information

• Verified date: March 2016
• Source: Liverpool Heart and Chest Hospital NHS Foundation Trust
• Contact: n/a
• Is FDA regulated: No
• Health authority: United Kingdom: Research Ethics Committee
• Study type: Interventional

Clinical Trial Summary

Atrial fibrillation (AF) is the commonest condition affecting the rhythm of the heart and causes an irregular and often rapid heartbeat. Developing this condition may cause significant health problems and symptoms that affect normal day-to-day activities. Patients with AF also have a shorter life expectancy on average. Tablets used to try to normalise the heart rhythm rarely work well. As a result, doctors have devised a treatment to try to cure this condition. Special wires (called catheters) are used to deliver heat energy (called ablation) on the inside surface of the heart. This technique has been used more and more in recent years for patients with troublesome symptoms due to AF.

The aim of the treatment is to draw lines of ablation in specific places in the heart. Unfortunately, a lot of patients (almost 50%) get AF again after this treatment and most of these patients have a second treatment performed. It is usually found at this second treatment that gaps have developed in the lines of ablation that were drawn the first time around. The investigators think that electively doing a second treatment to close these gaps a couple of months after the first treatment may mean that fewer of these patients will get AF again in the future. The investigators also want to find out what factors make a line of ablation less likely to develop gaps.

In this study, participants will be assigned to one of two groups:

1. a "standard care" group, who will have a single treatment initially.

2. a "repeat study" group, who will have the initial treatment followed by a second treatment 8-10 weeks later.

For patients in the "repeat study group", investigators will see how many have developed gaps since their first treatment. The investigators will look at where these gaps are and will compare this with information collected during the first treatment to try to work out why the gap has developed. Any gaps found at the second treatment will be closed again.

All participants will then be monitored carefully over 12 months to see how many from each group get AF again. To do this, all participants will be given a handheld heart rhythm monitor to keep until the end of the study. This device is simple to use. Participants will be asked to make a 30 second recording of their heart rhythm each day and also whenever they have symptoms. These recordings will be downloaded at review appointments arranged 6 weeks, 3 months, 6 months and 12 months after the initial ablation procedure.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 80
• Est. completion date: February 2016
• Est. primary completion date: February 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Aged over 18 years

• Current pattern of paroxysmal AF (defined as electrocardiogram (ECG)-proven episodes of AF which are self-limiting and last less than 7 days on each occasion, or which were cardioverted electrically or pharmacologically less than 48 hours from onset)

• Due to undergo pulmonary vein isolation by radiofrequency (RF) ablation

Exclusion Criteria:

• Inability or unwillingness to receive oral anticoagulation with warfarin or alternative anticoagulant drug

• Previous ablation procedure for AF

• Unwillingness or inability to complete the required follow-up arrangements

• Current pattern of persistent (episodes of AF which last longer than 7 days or which last longer than 48 hours but require electrical or pharmacological cardioversion) or permanent AF

• Prior prosthetic mitral valve replacement or severe structural cardiac abnormality

• Reversible cause for AF

• Known infiltrative cardiomyopathy

• Known severe left ventricular systolic function (ejection fraction <35%)

• Pregnancy

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Atrial Fibrillation

Intervention

Procedure:
• Repeat PVI
Repeat EP study 8-10 weeks post-initial PVI with re-isolation of PV reconnection

Locations

Country	Name	City	State
United Kingdom	Liverpool Heart and Chest Hospital	Liverpool	Merseyside

Sponsors (2)

Lead Sponsor	Collaborator
Liverpool Heart and Chest Hospital NHS Foundation Trust	Biosense Webster, Inc.

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Pulmonary vein (PV) reconnection in patients with and without early recurrence	Comparison of prevalence, distribution and location of sites of late PV reconnection (8-10 weeks after their initial PVI) between patients with and without early recurrence in the "repeat study" group	3 months post-initial PVI	No
Other	Correlation between Visitag data and sites of PV reconnection	Correlation between initial Force-Time-Power Integral (as assessed using Visitag™) and a) sites of acute PV reconnection (including those unmasked by adenosine), and b) late PV reconnection (8-10 weeks after their initial PVI)	4 months post-inital PVI	No
Primary	Atrial tachyarrhythmia (AT) recurrence	The proportion of patients maintaining freedom from AT for 12 months post-initial PVI (after an initial 12 week blanking period)	12 months post-initial pulmonary vein isolation (PVI)	No
Secondary	Quality of life measures	Quality of life 12 months after initial ablation, as quantified by the validated Atrial Fibrillation Effect on Quality of Life (AFEQT) questionnaire.	12 months post-initial PVI	No
Secondary	Time to recurrence	Time to first AT recurrence after the initial blanking period	12 months post-initial PVI	No
Secondary	Comparison of major complication rates	Comparison of major complication rates (occurring within 30 days after a PVI procedure), to include cardiac tamponade, stroke/transient ischemic attack (TIA), myocardial infarction, pulmonary vein stenosis, phrenic nerve paralysis, oesophageal perforation/atrio-oesophageal fistula, major vascular complications and death	4 months post-initial PVI	Yes